OLON GROUP ANNOUNCES THE ACQUISITION OF GTP BIOWAYS GROUP
GTP Bioways Group is a French
company operating as Biotech CDMO (Contract Developing and Manufacturing
Organisation), specialising in R&D Services, process development and
production of mAbs, enzymes, proteins, nanodrugs, ADCs and F&F. GTP Bioways
Group, with multiple locations across France, specializes in delivering
comprehensive services to biopharmaceutical companies. From preclinical
development to commercial stages, the group focuses on utilizing cutting-edge
technologies to advance innovative therapies.
GTP Bioways Group's services
are seamlessly integrated with those of the Olon Biotech division. This
integration enables Olon Biotech to expand and diversify its technological
offerings, supporting every stage of the lifecycle, from R&D and preclinical
phases to industrialization, through microbial and mammalian fermentation and
biotherapeutics. Additionally, Olon Biotech will provide comprehensive services
for ...
Rodano site, that relies on one of the most extensive expertise in handling highly potent pharmaceutical principles at global level, has raised the level of containment up to the actual standards and very large scale putting in place a set of primary and secondary containment designed to avoid the active substances diffusion in the working environment.
GTP Bioways Group is a French
company operating as Biotech CDMO (Contract Developing and Manufacturing
Organisation), specialising in R&D Services, process development and
production of mAbs, enzymes, proteins, nanodrugs, ADCs and F&F. GTP Bioways
Group, with multiple locations across France, specializes in delivering
comprehensive services to biopharmaceutical companies. From preclinical
development to commercial stages, the group focuses on utilizing cutting-edge
technologies to advance innovative therapies.
GTP Bioways Group's services
are seamlessly integrated with those of the Olon Biotech division. This
integration enables Olon Biotech to expand and diversify its technological
offerings, supporting every stage of the lifecycle, from R&D and preclinical
phases to industrialization, through microbial and mammalian fermentation and
biotherapeutics. Additionally, Olon Biotech will provide comprehensive services
for the development and production of innovative ADC classes, offering a
complete solution from mAbs to linkers, payloads, conjugation, and
fill-and-finish processes
GTP BIOWAYS
GTP Bioways operates a
total of four sites in France (Toulouse, Labege, Veyre-Monton, and
Saint-Julien-en-Genevois) focused on development, clinical trial and cGMP
manufacturing. The headquarters are based in Toulouse.
The four centers operate
according to the highest quality standards, in line with reference GMPs and are
regularly inspected by the relevant regulatory authorities.
The business areas on which
GTP Bioways focuses include biologics manufacturing and ADC manufacturing (using
mammalian and microbial fermentation technology), nanodrug manufacturing, fill
and finish and analytical development – including HCP and immuno assay. In
particular, the company has consolidated a strong expertise in the business
areas in which it operates. Evidenced by a significative number of successfully
developed biological processes, the management of a broad and diversified range
of expression systems (mammalian, bacterial, yeast, insect cells) and molecules
(mAbs, antibody fragments, cytokines, fusion proteins, enzymes, antigens). In
addition, the group possesses significant expertise in bioconjugation and fill &
finish. The CDMO services offered make up an integrated platform capable of
supporting customers from drug discovery, through the entire development
process with a special focus on the pre-clinical phase, phase I and phase II.
OLON STRATEGY AND EXPANSION
OF CAPACITY
Since its foundation, Olon
Group has consistently pursued a strategy of growth, consolidation, and global
market expansion through both internal development and strategic acquisitions.
Each acquired business has contributed valuable expertise, enhancing Olon's
technological capabilities. In line with this strategy and aiming to advance
its innovative and high-tech offerings to customers, Olon has acquired GTP
Bioways Group. GTP Bioways Group’s specific capabilities in fully supporting
CDMO biotechnology projects also in the early phase of new molecule development
(pre-clinical, phase I and phase II), perfectly complements Olon's current
assets, to enrich and broaden the offering to customers.
“The acquisition of GTP Bioways
Group implies a strong and significant strengthening of Olon's service pipeline
with the aim of creating new business opportunities, acquiring new customers
and high-potential market areas, and ultimately continuing the company's
growth” stated
Paolo Tubertini, CEO Olon
Group.
In Q3 2024, Olon will
finalise its €25m investment in a facility operating under extremely high
containment, fully dedicated to the development and the production of Ultra
High Potent API - payloads and payload-linkers for antibody-drug conjugates
(ADCs). Olon relies on more than four
decades of experience in manufacturing cytotoxic products. With the acquisition
of GTP Bioways, Olon Biotech will be able to offer full services for the
development and production of ADCs, capable of supplying everything from mAbs
to linkers, payloads, conjugation and fill and finish.
“ADC class is highly
promising and extremely challenging as well, as they require specific
capabilities to handle different modalities with strict containment
regulations. This required high level of control ensures the safest environment
for ADC payload-linker production and product integrity, that can only be
reached leveraging over decades of expertise in containment for cytotoxic
anticancer production, focusing on full control of cross-contamination,
operator protection and extensive training” commented Paolo
Tubertini.
Antibody–drug conjugates (ADCs) are an
important new class of oncolo...
